Recombinant Mouse PLA2R1 Protein, CF

Catalog #: 5367-PL Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
5367-PL-050

R&D Systems Recombinant Proteins and Enzymes

1 Image

Product Details

Supplemental Products

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Mouse PLA2R1 Protein, CF Summary

Product Specifications

Purity

>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its binding ability in a functional ELISA.

When Recombinant Human PLA2G1B (Catalog # 5018-PL) is immobilized at 5 μg/mL (100 μL/well), the concentration of Recombinant Mouse PLA2R1 that produces 50% of the optimal binding response is found to be approximately 1.5-7.5 μg/mL.

Source

Mouse myeloma cell line, NS0-derived mouse PLA2R1 protein
Gln27-Gly1392, with a C-terminal 6-His tag

Accession #

NP_032893

N-terminal Sequence
Analysis

No results obtained: Gln27 predicted (N-sequencing might be blocked)

Predicted Molecular Mass

157.5 kDa

SDS-PAGE

150-170 kDa, reducing conditions

Product Datasheets

5367-PL

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

5367-PL

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution	Reconstitute at 500 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Reconstitution Calculator

Background: PLA2R1

PLA2R1 (phospholipase A2 receptor 1) also called muscle (M-)type PLA2R or secretory (s)PLA2R is a 180-200 kDa type I transmembrane glycoprotein that is a member of subgroup VI of the C-type lectin superfamily (1-3). The 1487 amino acid (aa) mouse PLA2R1 contains a 26 aa signal sequence, a 1370 aa ECD, a 21 aa transmembrane sequence, and a 70 aa cytoplasmic domain with an endocytosis motif. The ECD contains one ricin B-type lectin domain (aa 42-165), a fibronectin type II region (aa 176-224), and eight C-type lectin carbohydrate recognition domains (CRDs, aa 241-1377) (1-3). CRDs 3-5 are the major PLA2 binding site (1, 3). The mouse PLA2R1 ECD shares 75% and 86% aa identity with human and rat PLA2R1, respectively. One isoform shows a 35 aa N-terminal extension, and a potentially secreted isoform contains a 10 aa substitution for aa 680-1487 (4). Matrix metalloproteinases can generate a 180 kDa soluble inhibitory form in mouse serum that retains PLA2 binding activity (3, 5). Mouse PLA2R1 is widely expressed, including on type II alveolar cells, neutrophils and mast cells, and binds mouse secretory PLA2s IB, IIA, IIE, IIF and X, and snake venom PLAs (1-3, 5-8). Among mammals, PLA2R1 ligand recognition is mainly species‑specific (3). PLA2R1 can be anti‑inflammatory by inhibiting PLA2‑induced release lipid mediators such as arachadonic acid (5 7, 9). PLA2R1 can also mediate internalization and clearance of PLA2s (10). PLA2R1 can also be pro‑inflammatory, and its deletion in mouse reduces susceptibility to LPS-induced endotoxic shock (8). Engagement activates the MAPK/ERK signaling pathway and enhances pro-inflammatory cytokine release (6, 8, 11). PLA2 binding can stimulate cell adhesion, proliferation or senescence, neutrophil elastase release, and smooth muscle contraction (6, 9, 12). All PLA2R1 intracellular signaling is largely independent of ligand phospholipase activity (6, 11).

References

Higashino, K-I. et al. (1994) Eur. J. Biochem. 225:375.
Lambeau, G. et al. (1994) J. Biol. Chem. 269:1575.
Hanasaki, K. (2004) Biol. Pharm. Bull. 27:1165.
SwissProt Accession Q62028.
Higashino, K-I. et al. (2002) J. Biol. Chem. 277:13583.
Silliman, C.C. et al. (2002) Am. J. Physiol. Cell Physiol. 283:C1102.
Rouault, M. et al. (2007) Biochemistry 46:1647.
Hanasaki, K. et al. (1997) Biol. Chem. 272:32792.
Ancian, P. et al. (1995) Biochemistry 34:13146.
Yokota, Y. et al. (2001) FEBS Lett. 509:250.
Granata, F. et al. (2005) J. Immunol. 174:464.
Augert, A. et al. (2009) EMBO Rep. 10:271.

Long Name

Phospholipase A2 Receptor 1, 180kDa

Entrez Gene IDs

22925 (Human); 18779 (Mouse); 295631 (Rat)

Alternate Names

180 kDa secretory phospholipase A2 receptor; CLEC13C; CLEC13CC-type lectin domain family 13 member C; phospholipase A2 receptor 1, 180kDa; PLA2G1R; PLA2IR; PLA2R1; PLA2-RM-type receptor; PLA2Rphospholipase A2 receptor 1, 180kD; secretory phospholipase A2 receptor